TickerFacts.

Compare

Krystal Biotech, Inc. vs Immunocore Holdings plc vs Twist Bioscience Corp vs Tarsus Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearKrystal Biotech, Inc.
KRYS		Immunocore Holdings plc
IMCR		Twist Bioscience Corp
TWST		Tarsus Pharmaceuticals, Inc.
TARS
Year ended2025-12-312025-12-312025-09-302025-12-31
Revenue$389.13M$400.02M$376.57M$451.36M
Revenue growth (YoY)+33.9%+29.0%+20.3%+146.7%
Gross marginn/an/a50.7% (computed)n/a
Operating margin41.5%-11.3%-36.2%-15.7%
Net margin52.6%-8.9%-20.6%-14.7%
Net income$204.83M-$35.51M-$77.67M-$66.42M
EPS (Diluted)$6.84-$0.71-$1.30-$1.59
Operating cash flow$200.87M-$10.71M-$47.63M-$12.45M
Free cash flow$188.91M-$15.05M-$75.63M-$22.31M
Cash & equivalents$496.30M$467.71M$183.05M$183.64M
Total assets$1.33B$1.07B$641.86M$562.16M
Total liabilities$114.23M$686.24M$168.90M$218.73M
Shareholders' equity$1.22B$381.03M$472.96M$343.43M
Return on year-end equity16.8%-9.3%-16.4%-19.3%
Shares outstanding29.19M50.69M60.63M42.55M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearKrystal Biotech, Inc.Immunocore Holdings plcTwist Bioscience CorpTarsus Pharmaceuticals, Inc.
Latest$389.13M
Ended 2025-12-31		$400.02M
Ended 2025-12-31		$376.57M
Ended 2025-09-30		$451.36M
Ended 2025-12-31
1 year earlier$290.51M
Ended 2024-12-31		$310.20M
Ended 2024-12-31		$312.97M
Ended 2024-09-30		$182.95M
Ended 2024-12-31
2 years earlier$50.70M
Ended 2023-12-31		$249.43M
Ended 2023-12-31		$245.11M
Ended 2023-09-30		$17.45M
Ended 2023-12-31
3 years earlier$0
Ended 2022-12-31		$174.36M
Ended 2022-12-31		$203.56M
Ended 2022-09-30		$25.82M
Ended 2022-12-31
4 years earlier$0
Ended 2021-12-31		$36.48M
Ended 2021-12-31		$132.33M
Ended 2021-09-30		$57.03M
Ended 2021-12-31